Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07257068 · ClinicalTrials.gov registry record · NA
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
A NA study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT07257068: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT07257068 is a NA study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07257068, a NA study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
Interventions
- OTHER Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-09-14 |
| Est. Completion | 2029-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07257068
The ClinicalTrials.gov registry entry for NCT07257068 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infliximab is the first listed.
NCT07257068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07257068 about?
NCT07257068 is a clinical study titled "Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study". To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
What is the current status of trial NCT07257068?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 14 participants. The study started on 2026-09-14. Estimated completion is 2029-12-31.
What interventions are being tested in trial NCT07257068?
The interventions under investigation include: Infliximab (OTHER).
Who is sponsoring clinical trial NCT07257068?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.